BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Since Gleevec (imatinib mesylate, STI571) was approved by the FDA as first-line treatment for chronic myeloid leukemia with the oncoprotein BCR-ABL expression in 2001, molecular targeted therapy for various cancers has become an area of intense basic science and clinical research.